Stay updated on FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Sign up to get notified when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.

Latest updates to the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page
- CheckyesterdayChange DetectedRevision tag updated from v3.5.3 to v3.5.4 on the page, indicating a newer version of the content.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe version/release label at the bottom of the page was updated from Revision: v3.5.0 to Revision: v3.5.3.SummaryDifference0.0%

- Check45 days agoChange DetectedLocation in Italy updated from Padua to Padova (35128); the Padova site is now listed and the Padua listing removed.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No changes to study data or page layout.SummaryDifference0.0%

- Check74 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; this seems to be a small internal site update with no visible changes to study content.SummaryDifference0.0%

- Check95 days agoChange DetectedGastric cancer added as a related topic/keyword and Genetic and Rare Diseases Information Center resources linked; the page revision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-03 Derazantinib Combo in Gastric Adenocarcinoma Clinical Trial page.